How To Calculate Dissolution

Calculate the dissolution rate of a substance based on key parameters. Enter the required values below to determine how quickly a material dissolves under specific conditions.

Understanding Dissolution Fundamentals

Dissolution is the process by which a solid substance dissolves in a solvent to form a solution. This phenomenon is governed by several key factors that determine how quickly and completely a substance will dissolve. Understanding these factors is essential for accurate dissolution calculations in pharmaceutical, chemical, and environmental applications.

Key Factors Affecting Dissolution Rate

1. Particle Size: Smaller particles have greater surface area relative to volume, increasing dissolution rate according to the Noyes-Whitney equation.
2. Temperature: Higher temperatures generally increase dissolution rates by providing more kinetic energy to solvent molecules.
3. Agitation: Mechanical stirring or shaking increases the rate by reducing the thickness of the diffusion layer around particles.
4. Solvent Properties: The chemical nature of the solvent (polarity, pH) significantly affects solubility.
5. Drug-Solvent Interactions: Hydrogen bonding, ionic interactions, and other molecular forces play crucial roles.

The Noyes-Whitney Equation

The foundational equation for dissolution rate is:

dC/dt = (D × A × (Cs – C)) / (h × V)

Where:

• dC/dt = dissolution rate
• D = diffusion coefficient
• A = surface area of the dissolving solid
• Cs = saturation solubility
• C = concentration of drug in solution at time t
• h = thickness of the diffusion layer
• V = volume of the dissolution medium

Step-by-Step Dissolution Calculation Process

Step 1: Determine Key Parameters

Before performing calculations, gather the following essential data:

Parameter	Typical Units	Measurement Methods
Substance mass	milligrams (mg)	Analytical balance (±0.1mg)
Solvent volume	milliliters (mL)	Volumetric flask or graduated cylinder
Temperature	Celsius (°C)	Calibrated thermometer (±0.1°C)
Particle size	micrometers (μm)	Laser diffraction or sieve analysis
Agitation speed	revolutions per minute (rpm)	Magnetic stirrer or paddle apparatus

Step 2: Calculate Surface Area

For spherical particles, surface area (A) can be calculated using:

A = 4πr² × n

Where r is the particle radius and n is the number of particles. For irregular particles, use specific surface area (SSA) values typically provided in material specifications.

Step 3: Determine Diffusion Coefficient

The diffusion coefficient (D) depends on:

• Molecular weight of the solute
• Viscosity of the solvent
• Temperature (follows Stokes-Einstein equation)

Typical D values range from 1×10⁻⁵ to 1×10⁻⁹ cm²/s for pharmaceutical compounds in aqueous solutions.

Step 4: Apply the Dissolution Equation

Using the collected parameters, plug values into the Noyes-Whitney equation. For practical calculations, many pharmaceutical scientists use simplified models like:

% Dissolved = (Amount dissolved / Initial amount) × 100

Step 5: Validate Results

Compare calculated values with:

• Published solubility data for the compound
• Empirical dissolution testing results
• USP/NF dissolution acceptance criteria (typically Q=80% in 45 minutes for IR tablets)

Advanced Dissolution Modeling Techniques

Computational Approaches

Modern dissolution modeling incorporates:

1. Molecular Dynamics Simulations: Atomistic-level modeling of solvent-solute interactions
2. Finite Element Analysis: For complex geometries and flow patterns
3. Machine Learning Models: Trained on large dissolution datasets to predict behavior

Biopharmaceutics Classification System (BCS)

The BCS categorizes drugs based on solubility and permeability:

Class	Solubility	Permeability	Dissolution Considerations
I	High	High	Rapid dissolution, generally no rate-limiting step
II	Low	High	Dissolution rate-limiting, formulation critical
III	High	Low	Permeability rate-limiting, dissolution less critical
IV	Low	Low	Problematic, requires special formulation approaches

In Vitro-In Vivo Correlation (IVIVC)

Establishing IVIVC involves:

1. Developing Level A correlation (point-to-point relationship between in vitro dissolution and in vivo absorption)
2. Using convolution/deconvolution techniques to model plasma concentration profiles
3. Validating with clinical pharmacokinetic data

Successful IVIVC can support biowaivers for post-approval changes (per FDA guidance).

Practical Applications of Dissolution Calculations

Pharmaceutical Development

• Formulation Optimization: Selecting excipients that enhance dissolution of poorly soluble APIs
• Quality Control: Batch-to-batch consistency testing
• Regulatory Compliance: Meeting USP/EP/JP dissolution test requirements

Environmental Science

• Predicting contaminant mobility in soil and water systems
• Modeling pesticide dissolution and leaching potential
• Assessing nanoparticle dissolution in ecological toxicity studies

Material Science

• Designing controlled-release fertilizers in agriculture
• Developing biodegradable polymers with predictable dissolution profiles
• Optimizing 3D-printed materials with soluble supports

Common Challenges and Solutions

Dealing with Poorly Soluble Compounds

Strategies for BCS Class II/IV drugs:

Approach	Mechanism	Example Technologies	Typical Improvement
Particle Size Reduction	Increased surface area	Nanomilling, spray drying	2-10× dissolution rate
Salt Formation	Enhanced solubility through ionization	HCl, mesylate, tosylate salts	10-1000× solubility
Amorphous Solid Dispersions	High-energy solid state	Spray-dried dispersions, hot-melt extrusion	10-100× dissolution rate
Surfactant Systems	Micelle formation	Polysorbates, Cremophor EL	3-20× apparent solubility
pH Modification	Ionization of weak acids/bases	Buffer systems, enteric coatings	Varies with pKa

Handling Non-Sink Conditions

When drug concentration approaches solubility (Cs – C → 0):

• Use larger dissolution volumes (maintain Cs/C > 3)
• Implement continuous flow-through systems
• Apply mathematical corrections to dissolution data

Addressing Polymorphic Forms

Different crystalline forms can show:

• 2-10× differences in dissolution rates
• Variations in stability and bioavailability
• Regulatory requirements for polymorph control

The USP Stimuli article provides guidance on handling polymorphic forms in dissolution testing.

Regulatory Considerations for Dissolution Testing

USP General Chapters

Key dissolution-related chapters:

• ⟨711⟩ Dissolution: Standard test procedures and apparatus specifications
• ⟨724⟩ Drug Release: For extended-release dosage forms
• ⟨1088⟩ In Vitro and In Vivo Evaluation: IVIVC guidance
• ⟨1092⟩ Dissolution Procedure: Development and validation

ICH Guidelines

International Council for Harmonisation documents:

• Q6A: Specifications for drug substances and products
• Q8(R2): Pharmaceutical development including dissolution as a critical quality attribute
• Q9: Quality risk management applied to dissolution method development

FDA Dissolution Guidance Documents

Critical FDA resources include:

• Dissolution Testing of Immediate Release Solid Oral Dosage Forms (1997)
• Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations (1997)
• Product-specific guidance documents for generic drug development

Emerging Trends in Dissolution Science

Biorelevant Dissolution Testing

Incorporating physiological factors:

• Simulated gastric and intestinal fluids with enzymes
• Dynamic pH changes mimicking GI transit
• Lipid-based media for poorly soluble compounds
• Mechanical stress modeling peristaltic movements

Miniaturized Dissolution Systems

Advantages of micro-scale testing:

• Reduced API requirements (as low as 1-5 mg)
• High-throughput screening capabilities
• Early-stage formulation development support
• Automated data collection and analysis

Artificial Intelligence in Dissolution Prediction

AI applications include:

• Neural networks trained on historical dissolution data
• Predictive modeling of formulation performance
• Optimization of dissolution test conditions
• Digital twins of dissolution apparatus for virtual testing

Research from University of Connecticut’s Pharmaceutics department has shown AI models can predict dissolution profiles with >90% accuracy for new chemical entities.

Frequently Asked Questions

What is the difference between solubility and dissolution?

Solubility refers to the maximum amount of solute that can dissolve in a given solvent at equilibrium (thermodynamic property). Dissolution describes the dynamic process of achieving that equilibrium (kinetic property). A compound can have high solubility but slow dissolution (e.g., large crystals), or low solubility but rapid dissolution (e.g., nanoparticles).

How does pH affect dissolution?

pH influences dissolution primarily through its effect on ionization:

• Acidic drugs: More soluble at low pH (stomach), less soluble at high pH (intestine)
• Basic drugs: More soluble at high pH, less soluble at low pH
• Neutral drugs: Generally pH-independent solubility

The Henderson-Hasselbalch equation quantifies this relationship: pH = pKa + log([ionized]/[unionized]).

What are the most common dissolution apparatus?

USP recognizes seven standard apparatus:

1. Basket: Rotating wire mesh basket (for tablets, capsules)
2. Paddle: Rotating paddle in vessel (most common for IR products)
3. Reciprocating Cylinder: For extended-release formulations
4. Flow-Through Cell: Continuous flow system for poorly soluble drugs
5. Paddle Over Disk: For transdermal patches
6. Rotating Cylinder: For suppositories and implants
7. Reciprocating Holder: For non-disintegrating dosage forms

How can I improve dissolution for a poorly soluble drug?

Consider this systematic approach:

1. Characterize the API (particle size, polymorphs, solubility across pH)
2. Evaluate salt forms or cocrystals
3. Test amorphous solid dispersions
4. Optimize excipients (surfactants, polymers)
5. Consider lipid-based formulations
6. Apply particle engineering (nanomilling, spray drying)
7. Conduct design of experiments (DoE) to optimize formulation

What are the acceptance criteria for dissolution testing?

Typical USP criteria for immediate-release dosage forms:

• Stage 1 (S1): ≥80% (Q) dissolved in 45 minutes (average of 6 units)
• Stage 2 (S2): If S1 fails, test additional 6 units; average of 12 units must be ≥80% in 45 minutes, with no unit < Q-15%
• Stage 3 (S3): If S2 fails, test additional 12 units; average of 24 units must be ≥80% in 45 minutes, with no more than 2 units < Q-15% and no unit < Q-25%

For modified-release products, criteria are product-specific and often involve multiple time points.